Serum biomarker analysis of neoadjuvant chemotherapy for locally advanced breast cancer according to pathologic response

Serum levels of epidermal growth factor receptor (EGFR), soluble Fas ligand (sFasL), migration inhibitory factor (MIF), and MMP-2 measured prior to the second round of neoadjuvant chemotherapy (NAC) in 27 patients achieving a pathologic complete response (pCR) or partial pathologic response (pPR) and 16 patients demonstrating no response (NR) to NAC. Cumulative receiver operating characteristics for patients achieving a pCR or pPR versus nonresponders to NAC based on serum levels of ErbB2, EGFR, MIF, MMP-2, and CD40 measured prior to the second cycle of NAC. Statistical significance: *< 0.05.<p><b>Copyright information:</b></p><p>Taken from "Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer"</p><p>http://breast-cancer-research.com/content/10/3/R45</p><p>Breast Cancer Research : BCR 2008;10(3):R45-R45.</p><p>Published online 12 May 2008</p><p>PMCID:PMC2481492.</p><p></p

Serum biomarker analysis of neoadjuvant chemotherapy for locally advanced breast cancer according to clinical response

Pretreatment serum levels of IL-6, IL-8, MMP-9, and tissue plasminogen activator inhibitor 1 (tPAI-1) were compared between 11 patients achieving a clinical complete response (cCR) and 12 patients demonstrating no response (NR) to neoadjuvant chemotherapy (NAC). Pretreatment serum levels of tPAI-1 were compared between 30 patients achieving a cCR or clinical partial response (cPR) and 12 patients demonstrating NR to NAC. Serum levels of insulin-like growth factor binding protein 1 (IGFBP-1) and IL-8 measured prior to the second round of NAC were compared between 11 patients achieving a cCR and 11 patients demonstrating NR to NAC. Cumulative receiver operating characteristics for responders versus nonresponders based on pretreatment serum levels of tPAI-1. Statistical significance: *< 0.05; **< 0.01.<p><b>Copyright information:</b></p><p>Taken from "Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer"</p><p>http://breast-cancer-research.com/content/10/3/R45</p><p>Breast Cancer Research : BCR 2008;10(3):R45-R45.</p><p>Published online 12 May 2008</p><p>PMCID:PMC2481492.</p><p></p